The proposed dosage form for this product is a sterile aqueous nebulising solution containing 20 % w/v acetylcysteine (200 mg/mL). The formulation is designed for administration via a nebuliser, which converts the liquid solution into a fine aerosol for inhalation into the respiratory tract, where it acts as a mucolytic to decrease mucus viscosity and facilitate expectoration and clearance (Yan et al., 2025).
A nebulising solution was selected as the proposed dosage form because the intended site of action of acetylcysteine is the respiratory tract. Nebulisers are the oldest yet modern method for delivering drugs directly to the lungs (Martin and Finlay, 2015). An aqueous solution was selected because liquid formulations are compatible with nebuliser devices and can be aerosolised to produce droplets suitable for inhalation.
A solution also provides a homogeneous dosage form in which the active pharmaceutical ingredient is dissolved throughout the formulation. Unlike semisolid dosage forms such as creams and ointments, which are designed primarily for application to the skin or mucous membranes, a liquid formulation can be aerosolised for pulmonary delivery. For these reasons, a sterile aqueous nebulising solution was selected as the most appropriate dosage form for the proposed acetylcysteine product.
Acetylcysteine is dissolved in the liquid vehicle, meaning that the API is distributed uniformly throughout the formulation. This helps ensure that each measured volume of solution contains a consistent concentration of acetylcysteine.
Unlike a suspension, the proposed formulation does not contain undissolved solid drug particles that can settle during storage. There is therefore no need to shake or redisperse the formulation before administration.
As the API is dissolved uniformly throughout the formulation, each measured volume should contain the same concentration of acetylcysteine. This assists with accurate and consistent dosing when the correct volume is administered.
As the proposed product is already in liquid form, it can be placed into a compatible nebuliser for conversion into an aerosol. No additional dissolution or preparation of a solid dosage form is required before nebulisation.
A nebulising solution cannot be administered without specialised equipment: it requires a compatible nebuliser device to convert the liquid formulation into an inhalable aerosol. The patient must therefore have access to the necessary equipment before the medication can be administered.
The formulation must remain a true solution throughout its shelf life. Changes in formulation conditions could potentially result in precipitation or the formation of visible particles, which would affect the homogeneity and suitability of the product.
The presence of water in the formulation may create a favourable environment for microbial growth. This is a major concern because the formulation and aerosol are intended for delivery to the respiratory tract, so effective microbial control and suitable storage conditions are important for maintaining product quality and safety.
A liquid formulation may be susceptible to chemical degradation during storage if appropriate formulation conditions are not maintained. Factors such as pH, temperature, light and exposure to oxygen may therefore need to be controlled to maintain product quality throughout its shelf life.
As the proposed product is a nebulising solution, acetylcysteine must be sufficiently soluble in the chosen vehicle to produce a clear and homogeneous formulation at the required concentration of 200 mg/mL. It must dissolve completely and remain in solution throughout the product's shelf life; undissolved particles or precipitation should be avoided, as this could affect both dose uniformity and suitability for nebulisation.
As the dosage form is a true solution, the vehicle acts as the medium in which the active pharmaceutical ingredient is dissolved. It must be suitable for pulmonary administration and capable of producing a stable and homogeneous solution at 200 mg/mL, necessary to maintain the homogeneity, stability and suitability of the final product for nebulisation.
The pH of the formulation can influence the stability and solubility of the active pharmaceutical ingredient, and could result in degradation or precipitation of the acetylcysteine. pH control also matters because the product is intended for direct administration to the respiratory tract, where an unsuitable pH may contribute to irritation during inhalation.
A formulation with an unsuitable osmolality may affect its tolerability and potentially contribute to airway irritation during inhalation. The tonicity of the formulation should be carefully considered during product development to ensure the final solution is appropriate and well tolerated for pulmonary administration.
Microbial control is an important consideration during the formulation and manufacture of the proposed nebulising solution. As the product is an aqueous formulation intended for administration to the respiratory tract, microbial contamination could affect the quality and safety of the product.
Chemical stability is important to ensure that acetylcysteine does not undergo degradation that could reduce the quality of the product. Physical stability is also necessary to ensure that the formulation remains a clear and homogeneous solution without precipitation or other undesirable changes during storage.
The acetylcysteine nebulising solution should be used with a compatible nebuliser device, and the patient should follow the manufacturer's instructions to ensure that the formulation is correctly aerosolised and administered.
The correct prescribed volume of the acetylcysteine solution should be placed into the nebuliser to ensure that the intended dose is administered.
The nebuliser should be cleaned according to the manufacturer's instructions after use, to prevent the accumulation of medication residue and minimize contamination.
Appropriate hygiene and handling should be maintained when preparing and administering the solution, to minimize the risk of contaminating the formulation or nebuliser equipment.
The product should be transported under appropriate temperature conditions to prevent excessive heat or cold from affecting the stability of the formulation.
The packaging should protect the product from breakage, leakage or damage during handling and transportation.
The container should remain securely sealed during transportation to protect the formulation from contamination.
Where required by the product's stability requirements, appropriate packaging should protect the formulation from exposure to light during transportation.